Navigation Links
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
Date:10/1/2008

NEW YORK, Oct. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2009 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 21, 2008. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President-Finance and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website http://www.frx.com and also on the website http://www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until October 31, 2008 at both websites and also by dialing 1-866-859-6142 (US investors) or +1-706-679-7668 (international investors), ID 67369178

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit http://www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oil palm plantations are no substitute for tropical rainforests, a new study shows
2. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
3. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
4. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
5. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
6. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
7. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
8. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
9. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
10. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
11. Nanotube forests grown on silicon chips for future computers, electronics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding ... know someone who suffers from hay fever, urticaria, asthma, atopic eczema or a ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... clients throughout the biopharma and life sciences industries, continue to be in demand ... Tunnell’s Kip Wolf will be speaking on “The State of Information Governance in ...
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased ... test was determined to be appropriate as a screening test at dairies and farms ... Charm EZ system, and the Charm EZ Lite system. These systems are a combination ...
(Date:6/20/2017)... ... June 20, 2017 , ... HorizonScan is ... which pose the most likely threat to their products at the annual IFT ... , IFT's annual food expo attracts over 20,000 attendees representing food science professionals ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):